Preclinical evidence for the use of anti-Trop-2 antibody-drug conjugate Sacituzumab govitecan in cerebral metastasized castration-resistant prostate cancer.
Weiten R, Niemann M, Below E, Friker LL, Ralser DJ, Toma M, Kristiansen G, Hahn O, Zechel S, Grünwald V, Bald T, Siewert J, Pietsch T, Ritter M, Hölzel M, Eckstein M, Alajati A, Krausewitz P, Klümper N.
Weiten R, et al.
Cancer Med. 2024 Jun;13(12):e7320. doi: 10.1002/cam4.7320.
Cancer Med. 2024.
PMID: 38895886
Free PMC article.